衰弱与多重用药对药物相关损害致医疗利用的影响:多中心队列研究
随着衰弱程度增加,因药物相关损害需要医疗利用的概率从约0.2升至0.4。
要点
- 衰弱与药物相关损害致医疗利用独立相关,OR=10.06(95%CI 2.06-49.26)。
- 衰弱程度增加时,药物相关损害致医疗利用概率从约0.2升至0.4。
- 用药数量增加也呈现类似概率上升趋势。
核心结论
- 衰弱与药物相关损害导致的医疗利用相关,且独立于多重用药。
- 通过整合健康与社会照护减轻衰弱负担,并减少不适当多重用药,可能降低药物相关损害相关的医疗利用。
研究设计与样本
- 排除标准为预期寿命有限、转至其他医院及未获得知情同意。
主要发现
- 药物相关损害导致的医疗利用与衰弱显著相关(OR=10.06,95%CI 2.06-49.26,P=0.004),独立于年龄、性别和用药数量。
- 随着衰弱程度增加,因药物相关损害需要医疗利用的概率从约0.2升至0.4。
- 用药数量增加时也观察到类似的概率上升趋势。
关键数值与推荐
- 药物相关损害需要医疗利用的定义包括:与MRH相关的初级、二级或三级照护咨询,含药物不良反应、不依从和用药错误。
- 药物相关损害通过三个来源数据判定:结构化电话访谈收集的患者/照护者报告、初级照护病历审查、以及前瞻性顾问主导的再入院审查。
- 衰弱使用采用标准化方法开发的衰弱指数(Frailty Index)测量。
- 边际估计值来自逻辑回归模型,用于检验药物相关损害致医疗服务利用概率与用药数量和衰弱的关系。
临床怎么用
- 对≥65岁出院患者应评估衰弱程度,衰弱者药物相关损害致医疗利用风险显著升高。
- 减少不适当多重用药的同时,需通过整合健康与社会照护减轻衰弱负担,以降低药物相关损害相关医疗利用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the association between frailty and medication-related harm requiring healthcare utilisation. DESIGN: Prospective observational cohort study. SETTING: Six primary and five secondary care sites across South East England, September 2013-November 2015. PARTICIPANTS: One thousand and two hundred and eighty participants, ≥65 years old, who were due for discharge from general medicine and older persons' wards following an acute episode of care. Exclusion criteria were limited life expectancy, transfer to another hospital and consent not gained. MAIN OUTCOME MEASURES: Medication-related harm requiring healthcare utilisation (including primary, secondary or tertiary care consultations related to MRH), including adverse drug reactions, non-adherence and medication error determined via the review of data from three sources: patient/carer reports gathered through a structured telephone interview; primary care medical record review; and prospective consultant-led review of readmission to recruiting hospital. Frailty was measured using a Frailty Index, developed using a standardised approach. Marginal estimates were obtained from logistic regression models to examine how probabilities of healthcare service use due to medication-related harm were associated with increasing number of medicines and frailty. RESULTS: Healthcare utilisation due to medication-related harm was significantly associated with frailty (OR = 10.06, 95% CI 2.06-49.26, P = 0.004), independent of age, gender, and number of medicines. With increasing frailty, the need for healthcare use as a result of MRH increases from a probability of around 0.2-0.4. This is also the case for the number of medicines. CONCLUSIONS: Frailty is associated with MRH, independent of polypharmacy. Reducing the burden of frailty through an integrated health and social care approach, alongside strategies to reduce inappropriate polypharmacy, may reduce MRH related healthcare utilisation.
引用
- Stevenson JM, Parekh N, Chua KC, et al. A multi-centre cohort study on healthcare use due to medication-related harm: the role of frailty and polypharmacy. Age Ageing. 2022. PMID: 35353136. doi:10.1093/ageing/afac054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。